AU2004324236B2 - Neuron regeneration - Google Patents

Neuron regeneration Download PDF

Info

Publication number
AU2004324236B2
AU2004324236B2 AU2004324236A AU2004324236A AU2004324236B2 AU 2004324236 B2 AU2004324236 B2 AU 2004324236B2 AU 2004324236 A AU2004324236 A AU 2004324236A AU 2004324236 A AU2004324236 A AU 2004324236A AU 2004324236 B2 AU2004324236 B2 AU 2004324236B2
Authority
AU
Australia
Prior art keywords
gene silencing
molecule
seq
sirna
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004324236A
Other languages
English (en)
Other versions
AU2004324236A1 (en
Inventor
Zubair Ahmed
Martin Berry
Ann Logan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuregenix Ltd
Original Assignee
Neuregenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuregenix Ltd filed Critical Neuregenix Ltd
Publication of AU2004324236A1 publication Critical patent/AU2004324236A1/en
Application granted granted Critical
Publication of AU2004324236B2 publication Critical patent/AU2004324236B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004324236A 2004-10-22 2004-10-22 Neuron regeneration Ceased AU2004324236B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2004/004504 WO2006043014A1 (en) 2004-10-22 2004-10-22 Neuron regeneration

Publications (2)

Publication Number Publication Date
AU2004324236A1 AU2004324236A1 (en) 2006-04-27
AU2004324236B2 true AU2004324236B2 (en) 2010-12-09

Family

ID=34958935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004324236A Ceased AU2004324236B2 (en) 2004-10-22 2004-10-22 Neuron regeneration

Country Status (7)

Country Link
US (1) US7943755B2 (enExample)
EP (1) EP1802755A1 (enExample)
JP (1) JP4704435B2 (enExample)
CN (1) CN101084309A (enExample)
AU (1) AU2004324236B2 (enExample)
CA (1) CA2584921A1 (enExample)
WO (1) WO2006043014A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014077A2 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CN102666856B (zh) 2009-11-08 2016-04-06 夸克制药公司 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410323B1 (en) * 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
AU2002210791A1 (en) * 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
EP1675949A2 (en) * 2003-10-23 2006-07-05 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMED, Z. et al, Society for Neuroscience Abstract Viewer and Itinerary Planner, 2003, Vol. 2003, pages Abstract No. 816.7 *
HIGUCHI, H. et al, Biochemical and Biophysical Research Communications, 2003, Vol. 301, pages 804-809 *

Also Published As

Publication number Publication date
US20080253989A1 (en) 2008-10-16
JP4704435B2 (ja) 2011-06-15
CN101084309A (zh) 2007-12-05
AU2004324236A1 (en) 2006-04-27
CA2584921A1 (en) 2006-04-27
EP1802755A1 (en) 2007-07-04
US7943755B2 (en) 2011-05-17
WO2006043014A1 (en) 2006-04-27
JP2008516628A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
JP6197057B2 (ja) Ｈｓｐ４７発現の調節
AU2007215275B2 (en) Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
TWI658830B (zh) Ｈｓｐ47表現調控強化用類視色素脂質體
US20060035815A1 (en) Pharmaceutical compositions for delivery of ribonucleic acid to a cell
JP2016185150A (ja) Ｔｉｍｐ１およびｔｉｍｐ２発現の調節
EP1934359A2 (en) Pharmaceutical compositions for delivery of ribonucleic acid to a cell
Wu et al. Actions of neuropoietic cytokines and cyclic AMP in regenerative conditioning of rat primary sensory neurons
WO2010042530A2 (en) Nlrc5 as a target for immune therapy
US7943755B2 (en) Neuron regeneration
CN101818150B (zh) 神经元再生
KR101834841B1 (ko) 줄기세포의 고활성 유도 방법
KR20080044909A (ko) 세포 내로 리보핵산의 전달을 위한 약학 조성물
Xu et al. Cell-Astrocyte Integration and Inhibits Glial Scar Formation Ability
WO2007138236A1 (en) Sheddase enzymes for neuron growth
WO2024197320A2 (en) Targeting sf3b2 for axonal protection in central nervous system neurodegenerative diseases
KR101088764B1 (ko) Ｎｋ１ｒ 단백질 억제제를 포함하는 알코올 의존 예방 및 치료용 조성물
KR20220155585A (ko) Sirt1 발현을 사용하는 진단 방법
HK1235821B (en) Modulation of hsp47 expression
HK40025376B (en) Double-stranded rna molecule targeting ckip-1 and use thereof
HK40034234A (en) Ror2 inhibitors and use thereof in treating and/or preventing cartilage loss

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired